PGAP6

Across TCGA pan-cancer cohorts, PGAP6 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PGAP6 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PGAP6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PGAP6 expression acts as an unfavorable survival marker.

LUAD are the cancer types where PGAP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.353	0.798	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PGAP6–LUAD (OS)

Open the LUAD breakdown →